Investor Presentaiton

Strong underlying Q3 worldwide sales growth Merck WORLDWIDE SALES1,2 $16.0B +7% growth +6% ex-LAGEVRIO3 +8% ex-exchange, ex-LAGEVRIO3 Human Health $14.3B +10% growth +9% ex-LAGEVRIO3 +10% ex-exchange, ex-LAGEVRIO³ Animal Health $1.4B +2% growth +2% ex-exchange 1. Results attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue. 3. Excludes Lagevrio sales of $640 million in 3Q23 and $436 million in 3Q22. MERCK 10

View entire presentation